Natera (45E) Stock Overview
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 45E from our risk checks.
45E Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Natera, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$173.00 |
| 52 Week High | US$216.00 |
| 52 Week Low | US$162.00 |
| Beta | 1.7 |
| 1 Month Change | -2.26% |
| 3 Month Change | -8.47% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | 124.68% |
| Change since IPO | 784.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 45E | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.5% | -1.2% | -3.8% |
| 1Y | n/a | -7.1% | -5.1% |
Return vs Industry: Insufficient data to determine how 45E performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 45E performed against the German Market.
Price Volatility
| 45E volatility | |
|---|---|
| 45E Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 14.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 45E has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 45E's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 6,138 | Steve Chapman | www.natera.com |
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions.
Natera, Inc. Fundamentals Summary
| 45E fundamental statistics | |
|---|---|
| Market cap | €24.86b |
| Earnings (TTM) | -€180.08m |
| Revenue (TTM) | €2.00b |
Is 45E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 45E income statement (TTM) | |
|---|---|
| Revenue | US$2.31b |
| Cost of Revenue | US$812.93m |
| Gross Profit | US$1.49b |
| Other Expenses | US$1.70b |
| Earnings | -US$208.16m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.47 |
| Gross Margin | 64.75% |
| Net Profit Margin | -9.03% |
| Debt/Equity Ratio | 4.7% |
How did 45E perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/20 05:34 |
| End of Day Share Price | 2026/03/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Natera, Inc. is covered by 29 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Raymond Myers | Benchmark Company |